Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists
Lærke S. Gasbjerg, Natasha C. Bergmann, Signe Stensen, et al.
Peptides (2019) Vol. 125, pp. 170183-170183
Closed Access | Times Cited: 94

Showing 1-25 of 94 citing articles:

Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial
Bernhard Ludvik, Francesco Giorgino, Esteban Jódar, et al.
The Lancet (2021) Vol. 398, Iss. 10300, pp. 583-598
Closed Access | Times Cited: 416
The evolving story of incretins (GIP and GLP‐1) in metabolic and cardiovascular disease: A pathophysiological update
Michael A. Nauck, Daniel R. Quast, Jakob Wefers, et al.
Diabetes Obesity and Metabolism (2021) Vol. 23, Iss. S3, pp. 5-29
Closed Access | Times Cited: 219
Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction
Michael A. Nauck, David A. D‘Alessio
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 175
GIP as a Therapeutic Target in Diabetes and Obesity: Insight From Incretin Co-agonists
Jens J. Holst, Mette M. Rosenkilde
The Journal of Clinical Endocrinology & Metabolism (2020) Vol. 105, Iss. 8, pp. e2710-e2716
Open Access | Times Cited: 146
Metabolic Messengers: glucagon-like peptide 1
Fiona M. Gribble, Frank Reimann
Nature Metabolism (2021) Vol. 3, Iss. 2, pp. 142-148
Closed Access | Times Cited: 143
The metabolic impact of small intestinal nutrient sensing
Frank A. Duca, T.M. Zaved Waise, Willem T. Peppler, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 126
The expanding incretin universe: from basic biology to clinical translation
Daniel J. Drucker, Jens J. Holst
Diabetologia (2023) Vol. 66, Iss. 10, pp. 1765-1779
Open Access | Times Cited: 117
GLP-1 and GIP receptor signaling in beta cells – A review of receptor interactions and co-stimulation
Ashok Mayendraraj, Mette M. Rosenkilde, Lærke S. Gasbjerg
Peptides (2022) Vol. 151, pp. 170749-170749
Open Access | Times Cited: 82
Incretin hormones and type 2 diabetes
Michael A. Nauck, Timo D. Müller
Diabetologia (2023) Vol. 66, Iss. 10, pp. 1780-1795
Open Access | Times Cited: 78
Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective
Christophe De Block, Clifford J. Bailey, Carol Wysham, et al.
Diabetes Obesity and Metabolism (2022) Vol. 25, Iss. 1, pp. 3-17
Open Access | Times Cited: 71
The intestine as an endocrine organ and the role of gut hormones in metabolic regulation
Rula Bany Bakar, Frank Reimann, Fiona M. Gribble
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 12, pp. 784-796
Closed Access | Times Cited: 58
Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial
Leili Gao, Byung‐Wan Lee, Manoj Chawla, et al.
Nature Medicine (2023) Vol. 29, Iss. 6, pp. 1500-1510
Open Access | Times Cited: 50
Targeting the incretin system in obesity and type 2 diabetes mellitus
Saleem Ansari, Bernard Khoo, Tricia Tan
Nature Reviews Endocrinology (2024) Vol. 20, Iss. 8, pp. 447-459
Closed Access | Times Cited: 30
The Role of Incretins on Insulin Function and Glucose Homeostasis
Jens J. Holst, Lærke S. Gasbjerg, Mette M. Rosenkilde
Endocrinology (2021) Vol. 162, Iss. 7
Open Access | Times Cited: 81
Efficacy and safety of oral semaglutide in type 2 diabetes mellitus: A systematic review and meta-analysis
Aihua Li, Xiaorong Su, Shanshan Hu, et al.
Diabetes Research and Clinical Practice (2023) Vol. 198, pp. 110605-110605
Closed Access | Times Cited: 25
The Body weight Reducing Effects of Tirzepatide in People with and without Type 2 Diabetes: A Review on Efficacy and Adverse Effects
Thomas Leth Jensen, Andreas Brønden, Kristian Karstoft, et al.
Patient Preference and Adherence (2024) Vol. Volume 18, pp. 373-382
Open Access | Times Cited: 11
Emerging Pharmacotherapies for Obesity: A Systematic Review
Michail Kokkorakis, Marlene Chakhtoura, Caline Rhayem, et al.
Pharmacological Reviews (2024) Vol. 77, Iss. 1, pp. 100002-100002
Open Access | Times Cited: 9
Tirzepatide: a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) dual agonist in development for the treatment of type 2 diabetes
Juan P. Frías
Expert Review of Endocrinology & Metabolism (2020) Vol. 15, Iss. 6, pp. 379-394
Closed Access | Times Cited: 51
Do Gut Hormones Contribute to Weight Loss and Glycaemic Outcomes after Bariatric Surgery?
Dimitris Papamargaritis, Carel W. le Roux
Nutrients (2021) Vol. 13, Iss. 3, pp. 762-762
Open Access | Times Cited: 51
A review of the hormones involved in the endocrine dysfunctions of polycystic ovary syndrome and their interactions
Rebecca H K Emanuel, Josh P. Roberts, Paul D. Docherty, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 30
The Role of cAMP in Beta Cell Stimulus–Secretion and Intercellular Coupling
Andraž Stožer, Eva Paradiž Leitgeb, Viljem Pohorec, et al.
Cells (2021) Vol. 10, Iss. 7, pp. 1658-1658
Open Access | Times Cited: 33
Efficacy and safety of tirzepatide, dual GLP-1/GIP receptor agonists, in the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials
Qian Zhou, Xingxing Lei, Shunlian Fu, et al.
Diabetology & Metabolic Syndrome (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 15
Effects of Tirzepatide vs Semaglutide on β-Cell Function, Insulin Sensitivity, and Glucose Control During a Meal Test
Kieren J. Mather, Andrea Mari, Tim Heise, et al.
The Journal of Clinical Endocrinology & Metabolism (2024) Vol. 109, Iss. 12, pp. 3046-3054
Open Access | Times Cited: 5
Altered desensitization and internalization patterns of rodent versus human glucose‐dependent insulinotropic polypeptide (GIP) receptors. An important drug discovery challenge
Lærke S. Gasbjerg, Rasmus Syberg Rasmussen, Adrian Dragan, et al.
British Journal of Pharmacology (2024)
Open Access | Times Cited: 5
A direct look at the dysfunction and pathology of the β cells in human type 2 diabetes
Piero Marchetti, Mara Suleiman, Carmela De Luca, et al.
Seminars in Cell and Developmental Biology (2020) Vol. 103, pp. 83-93
Open Access | Times Cited: 33
Page 1 - Next Page

Scroll to top